Segment disclosures

Company overview

Crinetics Pharmaceuticals, Inc.

Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.

Revenue · Reported segment facts

3 dimension combinations 31 retained observations 9 reported periods

Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.

License And Service · Reportable Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=us-gaap:LicenseAndServiceMember;us-gaap:StatementBusinessSegmentsAxis=crnx:ReportableSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-301080000 USD20260803Open filing evidence
2026-01-01 – 2026-06-301508000 USD20260803Open filing evidence
2026-01-01 – 2026-03-31428000 USD20260507Open filing evidence
2025-01-01 – 2025-12-312276000 USD20260226Open filing evidence
2025-04-01 – 2025-06-301031000 USD20260803Open filing evidence
2025-01-01 – 2025-06-301392000 USD20260803Open filing evidence
2025-01-01 – 2025-03-31361000 USD20260507Open filing evidence
2024-01-01 – 2024-12-311039000 USD20260226Open filing evidence
2023-01-01 – 2023-12-314013000 USD20260226Open filing evidence

Product · Reportable Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=us-gaap:ProductMember;us-gaap:StatementBusinessSegmentsAxis=crnx:ReportableSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-3024038000 USD20260803Open filing evidence
2026-01-01 – 2026-06-3034344000 USD20260803Open filing evidence
2026-01-01 – 2026-03-3110306000 USD20260507Open filing evidence
2025-01-01 – 2025-12-315420000 USD20260226Open filing evidence
2025-04-01 – 2025-06-300 USD20260803Open filing evidence
2025-01-01 – 2025-06-300 USD20260803Open filing evidence
2025-01-01 – 2025-03-310 USD20260507Open filing evidence
2024-01-01 – 2024-12-310 USD20260226Open filing evidence
2023-01-01 – 2023-12-310 USD20260226Open filing evidence

Reportable Segment

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=crnx:ReportableSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-3025118000 USD20260803Open filing evidence
2026-01-01 – 2026-06-3035852000 USD20260803Open filing evidence
2026-01-01 – 2026-03-3110734000 USD20260507Open filing evidence
2025-01-01 – 2025-12-317696000 USD20260226Open filing evidence
2025-07-01 – 2025-09-30143000 USD20251106Open filing evidence
2025-01-01 – 2025-09-301535000 USD20251106Open filing evidence
2025-04-01 – 2025-06-301031000 USD20260803Open filing evidence
2025-01-01 – 2025-06-301392000 USD20260803Open filing evidence
2025-01-01 – 2025-03-31361000 USD20260507Open filing evidence
2024-01-01 – 2024-12-311039000 USD20260226Open filing evidence
2024-07-01 – 2024-09-300 USD20251106Open filing evidence
2024-01-01 – 2024-09-301039000 USD20251106Open filing evidence
2023-01-01 – 2023-12-314013000 USD20260226Open filing evidence